Tesaro Inc

Most Recent

  • uploads///TSRO
    Company & Industry Overviews

    Gauging Analysts’ Views on Tesaro Stock

    In November, of the total 21 analysts covering Tesaro (TSRO) stock, 13 have given it “buy” or higher ratings, and eight have given it “hold” ratings.

    By Kenneth Smith
  • uploads///cancer _
    Company & Industry Overviews

    Tesaro Stock Up over 16% on Rumors of Acquisition by Roche

    Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Tesaro Expects These Key Research Pipeline Milestones in 2019

    As per Tesaro’s (TSRO) third-quarter earnings conference call, the company is anticipating results from Phase 1/2 trial, AVANOVA.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Zejula Is a Major Growth Driver for Tesaro

    In its third-quarter earnings conference call, Tesaro (TSRO) has forecasted Zejula’s revenues for fiscal 2018 to fall in the range of $233 million to $238 million.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Tesaro’s Revenue Projections for Fiscal 2018?

    In its third-quarter earnings conference call, Tesaro (TSRO) narrowed its revenue guidance for fiscal 2018 from the previously projected range of $250 million to $265 million to $258 million to $265 million.

    By Margaret Patrick
  • uploads///medic _
    Company & Industry Overviews

    Why Clovis Oncology Stock Rose 48% in November

    On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.

    By Daniel Collins
  • uploads///lab _
    Company & Industry Overviews

    Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday

    On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.

    By Daniel Collins
  • uploads///TSRO
    Company & Industry Overviews

    Here’s What Tesaro’s Valuation Trend Indicates

    Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    PTC Therapeutics to Acquire Agilis Biotherapeutics

    On July 19, PTC Therapeutics (PTCT) agreed to acquire Agilis Biotherapeutics. The acquisition is expected to close during Q3 2018.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Talazoparib and Pidilizumab May Prove Complementary to Pfizer’s Existing Oncology Drugs

    Medivation has added its robust research pipeline with two promising investigational drugs, Talazoparib and Pidilizumab, to Pfizer’s oncology portfolio.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.